Quest Diagnostics Elects Director
News Jan 14, 2014
Tim Main currently serves as Chairman of the Board of Directors for Jabil Circuit, Inc.. Mr. Main joined Jabil in April 1987 and served in a number of operations and business development roles before being appointed Chief Executive Officer in September 2000, a role he held until 2013. As CEO, Mr. Main led Jabil's growth strategy, increasing annual revenues nearly fivefold to reach $17 billion in 2012, and expanding in Asia and other emerging markets.
"Tim has an exceptional record of generating business growth and shareholder value in a competitive, complex global market," said Steve Rusckowski, President and CEO, Quest Diagnostics. "This experience, coupled with his deep understanding of operations and supply chain management, will enable him to share a fresh, compelling perspective on Quest as we execute our strategy to restore growth, drive operational excellence and deliver disciplined capital deployment."
Daniel C. Stanzione, Ph.D., Chairman of the Board of Directors of Quest Diagnostics, added: "As the Chairman and former CEO of a large multinational with an operations-intensive business, Tim Main brings expertise in strategy, operations, and corporate governance that will be helpful to our company. We are pleased to welcome him to the Quest Board."
Mr. Main earned a B.S. degree from Michigan State University and Master of International Management degree from the American Graduate School of International Management (Thunderbird).
A New, Streamlined Approach to Diagnosing and Treating Bowel CancerNews
Researchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.READ MORE
New Rapid-fire Method Using Pathology Images & Tumor Data May Help Guide Cancer TherapiesNews
By combining data on pathology images of 13 types of cancer and correlating that with clinical and genomic data, researchers are able to identify tumor-infiltrating lymphocytes, which will enable cancer specialists to generate tumor-immune information from routinely gathered pathology slides.READ MORE